Condition: Tricuspid Valve Regurgitation · Pacemaker · ICD · Sponsor: Hazem Omran
The goal of this clinical trial is to record the incidence of newly developed or worsening tricuspid valve regurgitation (TR) following the implantation of a pacemaker or defibrillator with a transvenous lead. To collect this data, a transthoracic echocardiogram (TTE) with 3D imaging of the tricuspid valve (TV) will be performed before and after pacemaker implantation, with particular emphasis on assessing the tricuspid valve. Additionally, routine follow-up visits will be conducted at 6 and 12 months post-intervention, during which a TTE, ECG, NT-proBNP measurement, and pacemaker check will be performed.
This description comes directly from the study's public registry record.
Hazem Omran, MD · +49 5731 970 · homran@hdz-nrw.de
Lena Riemke-Maw, BSc · +49 5731 97 · lriemke-maw@hdz-nrw.de
Always discuss trial participation with your own doctor first.
| Herz- und Diabeteszentrum NRW | Bad Oeynhausen, North Rhine-Westphalia, Germany | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07342036